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Some experimental studies have suggested a beneficial eﬀect of the mammalian target of rapamycin (mTOR) inhibitor use on
hepatic and renal cyst growth in patients with autosomal dominant polycystic kidney disease (ADPKD). However, the results of
clinical studies are conflicting and the role of mTOR inhibitors is still uncertain. We report the case of a patient with ADPKD who
underwent deceased kidney transplantation because of an end-stage renal disease. The evolution was uneventful with an excellent
graft function under cyclosporine (CsA) monotherapy. Some years later, the patient developed a symptomatic hepatomegaly due
to growth of cysts. CsA was replaced by sirolimus, an mTOR inhibitor, in order to reduce or control the increase in the cyst and
liver volume. Despite the switch, the hepatic volume increased by 25% in two years. Finally sirolimus was stopped because of the
lack of eﬀect on hepatic cyst growth and the presence of sirolimus side eﬀects. The interest of our case resides in the followup by
MRI imaging during the mTOR inhibitor treatment and 15 months after the restart of the initial immunosuppressive therapy. This
observation indicates that mTOR inhibitors did not have significant eﬀect on cyst-associated hepatic growth in our patient, which
is consistent with some results of recent large clinical studies.
1. Introduction
The autosomal dominant polycystic kidney disease (ADPKD)
is the most common hereditary kidney disease and is the
fourth leading cause of end-stage renal disease in adults [1].
Studies outlined the role of mammalian target of rapamycin
(mTOR) in the pathogenesis of renal and hepatic cyst
formation. mTOR activity is upregulated in renal cyst lining
epithelial cells in patient with ADPKD, suggesting a potential
benefit of mTOR inhibitor treatment in reducing renal and
hepatic cyst growth. However, no randomized study has been
performed yet to evaluate the eﬀect of mTOR inhibitors in
reducing hepatic cyst growth in ADPKD patients. A slowing
eﬀect of mTOR inhibitors (or absence of slowing eﬀect of
mTOR inhibitors) on hepatic cysts growth still needs to be
determined. A long followup is needed, because many cyst
complications could change total kidney or hepatic volume.
The adequate dose of mTOR inhibitor to inhibit the mTOR
pathway with a minimum side eﬀect as well as the adequate
moment to initiate the treatment is also unknown and needs
to be investigated.
We report the case of an ADPKD patient who underwent
a kidney transplantation and developed a progressive volu-
minous symptomatic hepatomegaly. Sirolimus, an mTOR
inhibitors, was started because of preliminary data suggesting
a potential benefit of mammalian target of rapamycin
(mTOR) inhibitor therapy on hepatic cysts growth. But after
two years of treatment, we did not observe any improvement
in his condition and sirolimus was stopped.
2. Case Report
A 50-year-old man with autosomal dominant polycystic
kidney disease (ADPKD) evolved to end-stage renal failure
and hemodialysis was started in 1992. Because of voluminous
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kidneys, a right nephrectomy was performed in 1992,
followed by the left one in 1994. In April 1998, a deceased
donor kidney transplantation was performed in the right
iliac fossa. Induction therapy consisted in seven days of
polyclonal anti-T-cell globulin (thymoglobulin), because of
delayed graft function. Maintenance immunosuppression
consisted of cyclosporine (CsA) and prednisone. Steroids
were withdrawn in December 1998. No acute rejection
was observed. At one month, the serum creatinine was
130 µmol/L and the glomerular filtration rate was estimated
at 61mL/min/1.73m2 by MDRD. The serum creatinine
remained stable during the followup and was of 113 µmol/L
in March 2011.
During the followup in our outpatient clinic, the patient
suﬀered from recurrent episodes of hepatic cyst infections,
treated by antibiotics. In April 2007, bloating and abdominal
discomfort developed. An abdominal MRI was performed
showing a marked hepatomegaly with incomplete chronic
Budd-Chiari syndrome, due to extrinsic venous compression
by voluminous liver cysts. Because of worsening symptoms
and many hepatic cyst infections, a new MRI was performed
in June 2008, showing an increasing liver volume without
progression of the Budd-Chiari syndrome. The liver volume
was 3517mL at this time. Because of preliminary data sug-
gesting a potential benefit of mammalian target of rapamycin
(mTOR) inhibitors therapy on hepatic cyst growth, CsA was
stopped and sirolimus started at 0.5mg/d to achieve serum
levels between 4 and 6 ug/L (Table 1). MRIs were performed
during the mTOR therapy because of worsening symptoms,
and a followup was made with volumetric hepatic MRI.
Only total hepatic volume was measured. Six months later,
a new MRI showed a continuing increase in liver volume,
which was estimated at 3883mL. In November 2009, the liver
volume was 4240mL and in June 2010, 4400mL (Figure 1).
The chronic partial Budd-Chiari syndrome did not change.
Under sirolimus therapy, our patient did not report
adverse events like cutaneous rash, diarrhea, and aphthous
stomatitis, but he developed important legs edema. Hyper-
lipidemia was controlled with pravastatin and there was no
significant proteinuria. Because of the continuing increase
in liver volume (i.e., no significant eﬀect of sirolimus)
and the important discomfort due to bilateral legs edema,
sirolimus was stopped and CsA restarted in June 2010. The
diﬀerential diagnosis of leg edema was venous compression
due to hepatomegaly. After restarting CsA therapy, the leg
edema resolved, which was consistent with a sirolimus side
eﬀect. Fifteen months after sirolimus was stopped, a new
MRI was done. The liver volume was at 4700mL (Figure 1).
The average hepatic growth over the two years of sirolimus
therapy was of 37.5mL per month versus 20 mL per month
with cyclosporine.
3. Discussion
ADPKD is the most common hereditary kidney disease,
aﬀecting 1 in 400 to 1 in 10 000 births worldwide, and the
fourth leading cause of end-stage renal disease in adults [1].
ADPKD is a genetically heterogeneous disease charac-
terized by the development of cysts in the kidneys, liver,
Table 1: Serum level of sirolimus during treatment.
Date of dosage
(year/month/day)
Dose (mg/d) Sirolimus level (ug/L)
08.10.15 0.5 5.6
08.12.03 0.5 4
09.01.21 0.5 6.2
09.02.27 0.5 5.1
09.07.08 0.5 5.6
09.09.16 0.5 4.2
09.09.30 0.5 3.7
09.09.10 0.5 2.8
09.11.04 1 10.5
09.11.18 0.5 4.3
10.01.22 0.5 3
10.05.12 0.5 5.3
10.06.02 0.5 3.1
10.06.23 0.5 3.8
pancreas, seminal vesicles, and arachnoid membrane [1, 2].
Approximately 85% of cases are due to mutation in the
polycystic kidney disease 1 gene (PKD1) in chromosome
16 and 15% to polycystic kidney disease 2 gene (PKD2) in
chromosome 4 [3]. The glomerular filtration rate decline is
associated with the increase in kidney volume [4]. Patients
with PKD2mutation have a later onset of disease and develop
end-stage renal failure later than those with PKD1 mutation
[1].
75–90% of cases develop a polycystic hepatic disease. It
consists of proliferation and dilatation of biliary ductules
and peribiliary glands [1]. Estrogens stimulate hepatic cyst
cell proliferation, which explain why hepatic involvement is
more prevalent and more severe in a young woman than in
men. Polycystic hepatic disease is usually asymptomatic but
symptoms can occur by mass eﬀect or complications as cyst
hemorrhage, infection, torsion, or rupture [1].
Studies outlined the role of the mammalian target of
rapamycin (mTOR) in the pathogenesis of renal and hepatic
cyst formation and growing, and experimental studies
suggest mTOR inhibitors eﬃcacy as treatment in ADPKD.
mTOR is a kinase which integrates signals from cytokines,
hormones, and growth factors. It coordinates cell growth,
cell cycle progression, and proliferation. Human studies
show that mTOR activity is upregulated in renal cyst lining
epithelial cells in a patient with ADPKD. Recent studies
have shown that somatostatin and mTOR inhibitors may
have benefit hepatic cyst. Sirolimus, an mTOR inhibitor,
is used as an immunosuppressive drug mainly in trans-
plantation. Studies in rodent models show that mTOR
inhibition retarded hepatic cyst expansion. A study in
ADPKD patients after kidney transplantation suggested a
reduction in kidney and hepatic cyst volume in patients
treated with sirolimus compared to those treated with a
calcineurin inhibitor [5]. However, Sirolimus blood levels
to inhibit the mTOR pathway and avoid toxicity are not
known [6]. Based on those findings, a randomized, cross-
over study compared a 6-month treatment with sirolimus
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Figure 1: Hepatic volume since the initiation of mTOR inhibition
therapy. Two-year followup by MRI. Month 0 = switch CsA
to sirolimus. Month 24 = stop sirolimus because of absence of
reduction growth of the hepatic volume and edema attributed to
sirolimus.
or conventional therapy alone on the growth of kidney
volumemeasured in 21 patients with ADPKD and GFR equal
or more than 40mL/min [7]. 15 patients completed the
study, 7 with sirolimus. Compared with the pre-treatment
values, the posttreatment mean kidney volume increased
less on sirolimus than on conventional therapy, but without
significant diﬀerences. However, because of the small size
and the short followup of the SIRENA study, no firm
conclusions about the eﬀect of mTOR inhibition could be
reached. Recently, Serra et al. [8] randomized 100 patients
with a GFR of at least 70mL/min between sirolimus and
conventional therapy and followed them during 18 months
by MRI imaging. The conclusion was that in patients with
ADPKD and an early stage of kidney disease, sirolimus
did not stop the increase in kidney volume. Similary,
Walz et al. [9] randomized 433 patients followed during
two years to placebo versus everolimus, another mTOR
inhibitor therapy. This study showed that everolimus did
not significantly slow the increase of kidney volume during
the first year, but the benefit was not maintained after the
second year. Moreover, Canaud et al. compared two patients
who received renal transplant from a donor with a known
PKD1 mutation. One patient received steroids, tacrolimus,
and mycophenolate mofetil as immunosuppression therapy
and the other steroids, tacrolimus, and sirolimus. A five-year
follow up showed no diﬀerence in cyst growth between the
two patients [6]. No diﬀerence was noticed about the GFR
between the two groups. Therefore, based on the current
knowledge, the eﬀect of the mTOR inhibition on progression
of ADPKD remains uncertain.
The mTOR inhibition eﬀect on hepatic cyst progression
is unknown. Qian et al. [5] retrospectively examined 16 renal
transplant patients with ADPKD disease who were random-
ized between sirolimus-mycophenolate mofetil-prednisone
therapy and tacrolimus-mycophenolate mofetil-prednisone
therapy in another trial. After an average of 19.4 months
of treatment, the sirolimus regimen showed a reduction in
polycystic hepatic volume compared with tacrolimus, but
because of the small size, the retrospective form, and the
short followup of the study, no conclusion could be made
about the mTOR eﬀect on hepatic volume progression in an
ADPKD patient. Recently, He et al. [10] published a meta-
analysis of randomized controlled trials about the eﬃcacy
and safety of the mTOR inhibitor therapy in patients with
early ADPKD. Four studies were included, and analysis of
total kidney volume, cyst volume, parenchymal volume,
glomerular filtration rate, and adverse events wasmade. They
concluded that short-term mTOR inhibitor therapy may
slow down the increase in kidney volume and is relatively
safe but that the impact on the GFR was limited. Long-
term eﬃcacity and safety are still unknown. The adequate
moment to initiate the mTOR inhibitors therapy as well as
the dose of the medication needs to be investigated. Novali
et al. [11] used animal models of polycystic kidney disease
(PKD) to evaluate the eﬃcacy of low-dose levels versus high-
dose levels of sirolimus on renal cyst growth. They also
compared early and late initiation of the treatment. They
concluded that high dose of sirolimus given in an early
stage of the disease reduced significantly cyst formation in
ADPKD mouse models, where low-dose levels do not. When
initiated at a more advanced stage, low- and high-dose levels
of sirolimus have not significant eﬀects on cyst formation.
The high doses used in mouse models are 10 to 20 times
higher than those used for immunosuppressive therapy after
transplantation, beyond the levels tolerated by humans.
Side eﬀects were reported in the diﬀerent studies. Most
of them were controlled with medical treatment. Classi-
cal adverse events are aphtous stomatitis, rash, peripheral
edema, diarrhea, hyperlipidemia, proteinuria, and infection.
We reported the case of a patient in which we introduced
sirolimus to achieve serum levels between 4 and 6 ug/L
late in the disease progression. Our case raises several
questions concerning the use of mTOR inhibitors: when
should the treatment be introduced, which serum should be
targeted, and is it eﬀective and safe? In our patient, mTOR
inhibitor did not improve his abdominal condition and
induce important legs edema. Hepatic cysts epithelia express
a high level of mTOR suggesting that mTOR inhibitors may
have an eﬀect in downregulating hepatic cyst growth [5], but
no randomized study has been performed yet to evaluate
the eﬀect of this therapy. Randomized studies are needed
to determine the eﬃcacy of mTOR inhibitors on hepatic
cyst growing. A long followup is needed, because many
cyst complications could change the total kidney or hepatic
volume. The adequate dose of sirolimus to inhibit the mTOR
pathway with a minimum of side eﬀect [6] as well as the
adequate moment to initiate the therapy is still unknown
and needed to be investigated. The mTOR inhibitor eﬀect on
hepatic cysts growth still needs to be determined.
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